Targacept to Report Fourth Quarter and 2012 Financial Results on February 13, 2013

Targacept to Report Fourth Quarter and 2012 Financial Results on February 13, 2013

WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept Inc. (NAS: TRGT) , a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it will report financial results for the fourth quarter and year ended December 31, 2012 on Wednesday, February 13, 2013, after the U.S. financial markets close.

Management will discuss the fourth quarter and year-end financial results, provide a business and program update and discuss expectations for the future via conference call at 5:00 p.m. Eastern Time on Wednesday, February 13, 2013. The conference call may be accessed by dialing 800.322.2803 for domestic participants and 617.614.4925 for international callers (reference passcode 41520275). A replay of the conference call may be accessed from approximately 8:00 p.m. Eastern Time on February 13, 2013 through February 27, 2013 by dialing 888.286.8010 for domestic callers and 617.801.6888 for international callers (reference passcode 46454957).

A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept's website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacept's website for at least two weeks following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics(TM) for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept's clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.


Building Health, Restoring Independence®

Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Linnden Communications
Michelle Linn, 508-362-3087

KEYWORDS:   United States  North America  North Carolina


The article Targacept to Report Fourth Quarter and 2012 Financial Results on February 13, 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.